Search

Your search keyword '"Valim V"' showing total 233 results

Search Constraints

Start Over You searched for: Author "Valim V" Remove constraint Author: "Valim V"
233 results on '"Valim V"'

Search Results

1. Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions

2. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study

3. POS1247 CHARACTERIZATION OF 284 PATIENTS PRESENTING WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OF SJÖGREN DISEASE: RESULTS FROM THE SJÖGREN BIG DATA REGISTRY

4. POS1246 CHARACTERIZATION OF 785 PATIENTS WITH PULMONARY MANIFESTATIONS OF SJÖGREN DISEASE: RESULTS FROM THE BIG DATA SJÖGREN REGISTRY

5. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study

6. AB1316 SAFETY AND IMMUNOGENICITY OF TWO HETEROLOGOUS VACCINE SCHEDULES AGAINST SARS-CoV-2 IN PATIENTS WITH RHEUMATOID ARTHRITIS: BRAZILIAN MULTICENTER STUDY

7. POS0274 PROSPECTIVE EVALUATION OF THE EFFECT OF THE VACCINE AGAINST SARS-COV-2 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM SAFER STUDY

8. OP0223 THE EFFECT OF ANTIMALARIALS ON THE RISK AND SEVERITY OF BACTERIAL, VIRAL, FUNGAL AND SYSTEMIC-SPECIFIC INFECTIONS IN RHEUMATOID ARTHRITIS

9. AB0428 SAFETY AND PERSISTENCE OF TREATMENT WITH GOLIMUMAB VERSUS CERTOLIZUMAB IN RHEUMATOID ARTHRITIS: RESULTS FROM BIOBADABRASIL COHORT STUDY.

10. AB1283 COVID-19 WAS NOT TRIGGER FOR RHEUMATIC DISEASE ACTIVITY AFTER 6 MONTHS FOLLOW-UP: RESULTS FROM REUMACOV BRASIL REGISTER

11. POS0271 HETEROLOGOUS COVID-19 BOOSTER VACCINATION PRODUCED GREATER ANTIBODY TITERS IN AUTOIMMUNE DISEASE PATIENTS: DATA FROM MULTICENTRIC PROSPECTIVE PHASE IV SAFER STUDY

12. SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients

13. POS1285 IMMUNOGENICITY AND SAFETY OF THE CHADOX 1 COVID-19 VACCINE IN PATIENTS WITH AUTOIMMUNE DISEASES AND HEALTHY CONTROLS: DATA FROM SAFER STUDY

14. POS0242 THE EFFECT OF ANTIMALARIALS ON THE OVERALL SAFETY AND PERSISTENCE OF TREATMENT WITH BIOLOGIC AGENTS OR JAK INHIBITORS IN RHEUMATOID ARTHRITIS

15. POS0650 THE IMPACT OF OLD AGE ON THE PERSISTENCE AND SAFETY OF TREATMENT WITH BIOLOGIC AGENTS OR JAK INHIBITORS IN RHEUMATOID ARTHRITIS

16. AB1173 INCIDENT CASES OF COVID-19 AND VACCINATION ADHERENCE IN A MULTICENTRIC COHORT OF INFLAMMATORY ARTHRITIS IN BRAZIL

17. Influence of the age at diagnosis in the disease expression of primary Sjögren's syndrome: Analysis of 12,753 patients from the Sjögren Big Data Consortium

18. Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection

19. Influence of the age at diagnosis in the disease expression of primary Sjögren's syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium

20. SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients

21. AB0848 PARTICIPATION OF UNDERGRADUATE MEDICAL STUDENTS AS INVESTIGATORS IN A RHEUMATOLOGIC COHORT: IMPACT ON DEPRESSION, ANXIETY & STRESS SCALE

22. POS0676 SURVIVAL OF THE FIRST COURSE OF BIOLOGIC OR JAK INHIBITOR IN RHEUMATOID ARTHRITIS: ASSOCIATION WITH THE CHOICE OF AGENT AND CONCOMITANT CONVENTIONAL SYNTHETIC DMARDS

23. POS1252 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES ON CHRONIC USE OF HYDROXYCHLOROQUINE IN A LARGE BRAZILIAN COHORT – A 24-WEEK PROSPECTIVE STUDY

24. Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies

25. Influência do tabagismo em pacientes com artrite reumatoide em tratamento

26. How the age at diagnosis modifies the phenotype of primary Sjögren syndrome: analysis in 11.420 patients (Big data Sjögren project

27. LYMPHOMA ARISING AT THE TIME OF DIAGNOSIS OF PRIMARY SJOGREN SYNDROME: A HIGHLY-ACTIVE SYSTEMIC SUBSET OF THE DISEASE

28. Systemic manifestations of primary Sjogren's syndrome out of the ESSDAI classification : prevalence and clinical relevance in a large international, multi-ethnic cohort of patients

29. How immunological profle drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project)

30. Influence of epidemiology and ethnicity on systemic expression of primary Sjögren syndrome in 9974 patients

31. Sjögren big data project, the first example of data sharing in autoimmune diseases: analysis of 10475 worldwide patients

32. How the different systemic organ involvements are overlapped in patients with primary Sjogren syndrome: analysis using a mathematical model

33. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project)

34. Systemic Sjogren presenting without sicca syndrome: characterization of 240 patients according to the new 2017 ACR/EULAR Classification Criteria

35. How ethnicity modifies systemic activity of primary Sjogren syndrome: analysis of baseline ESSDAI scores in a multi-ethnic international cohort

36. Clinical and immunological disease patterns of primary Sjogren syndrome driven by gender and age at diagnosis

37. RISK FOR TUBERCULOSIS DURING TREATMENT WITH BIOLOGICAL THERAPY: IS IT TIME FOR REVIEWING SCREENING PROTOCOL? – RESULTS FROM BRAZILIAN REGISTRY OF BIOLOGICAL THERAPIES IN RHEUMATIC DISEASES (BIOBADABRASIL)

38. A North-South Worldwide Gradient in Systemic Activity of Primary Sjögren Syndrome : Increased Severe Disease in Patients from Southern Countries

39. Influence of epidemiology and ethnicity on systemic expression of primary Sjögren syndrome in 9974 patients

40. Baseline ESSDAI/DAS scores in 8061 patients with primary sjÖgren syndrome: characterization of systemic disease

41. SAT0457 SjÖgren big data project, the first example of data sharing in autoimmune diseases: analysis of 10475 worldwide patients

42. COVID-19 WAS NOT TRIGGER FOR RHEUMATIC DISEASE ACTIVITY AFTER 6 MONTHS FOLLOW-UP: RESULTS FROM REUMACOV BRASIL REGISTER.

43. SAFETY AND PERSISTENCE OF TREATMENT WITH GOLIMUMAB VERSUS CERTOLIZUMAB IN RHEUMATOID ARTHRITIS: RESULTS FROM BIOBADABRASIL COHORT STUDY.

44. Analysis Of 9302 Patients From The Big Data International Primary Sjogren Syndrome Cohort : Clinical Presentation At Diagnosis Of European Vs Non-European Patients

45. Baseline Essdai/ Das Scores In 8061 Patients With Primary Sjögren Syndrome : Characterization Of Systemic Disease

46. Predicting Survival In 6240 Patients With Primary Sjögren' Syndrome (Big Data Sjögren Project)

47. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

48. AB0160 Interferon-Γ-inducible kynurenines inflammation pathway: the missing link between disease activity and symptoms in sjÖgren's syndrome

49. OP0259-HPR Supervised walking improves aerobic capacity, exercise tolerance, fatigue and perceived improvement in women with primary sjÖgren's syndrome: a randomized controlled trial

50. SAT0270 Ultrasonography of major salivary glands in juvenile sjÖgren's syndrome – preliminary findings in a multi-center study

Catalog

Books, media, physical & digital resources